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Introduction
We previously reported a syndrome of intermittent fevers,
early-onset lacunar strokes, livedoid rash, hepatospleno-
megaly, immune deficiency, and systemic vasculopathy,
associated with loss-of-function mutations in CECR1. An
additional report by others expanded the clinical spectrum
to include patients with cutaneous polyarteritis nodosa.
Objectives
We now present clinical follow-up on our reported
5 patients and an additional 9 patients.
Patients and methods
We evaluated the 14 patients at the National Institutes of
Health. All patients were enrolled in an IRB approved
study. We performed whole-exome sequencing in the
initial 3 patients and their unaffected parents and candi-
date-gene sequencing in the other 11 patients. Clinical
information and radiographic and laboratory testing were
obtained at each visit.
Results
All patients had 2 mutations in CECR1. 11/14 patients
reported recurrent fevers.
10/14 patients had at least one stroke, with 8/10 before the
age of 5 years. Magnetic resonance imaging showed evidence
of acute or chronic small subcortical infarcts involving the
deep-brain nuclei and the brain stem, consistent with small-
vessel occlusions (lacunar strokes). Three patients had addi-
tional hemorrhagic strokes. In 10/10 patients, magnetic
angiography showed no evidence of cerebral vasculitis.
All 14 patients demonstrated livedo racemosa. Erythema-
tous papules or nodules were seen in 11 of these patients.
Hepato- and/or splenomegaly was observed in 10/14
with 3 patients demonstrating portal hypertension. One
patient developed a perforated small bowel requiring
resection.
Hypertension was noted in 2 patients. Prolonged QT
was reported in 3 patients.
12/14 demonstrated hematologic abnormalities including
anemia, leukopenia, and/or thrombocytopenia. Elevation of
acute phase reactants was reported in 13/14 patients.
Low serum iron was noted in 8/10 patients tested.
10/13 presented with hypogammaglobulinemia, how-
ever, this may reflect prior treatment with cyclopho-
sphamide in 3 patients.
Most patients had received a number of medications
over the course of their disease. It was our practice to
discontinue aspirin and/or anticoagulation in all of our
DADA2 patients. We observed striking improvement in
CRP, ESR, CBC, and serum iron in 10/12 patients
receiving anti-TNF agents.
Conclusion
We have expanded the clinical picture of our cohort of
patients with DADA2 to include multiple strokes, livedo
racemosa, cutaneous PAN, portal hypertension, hemato-
logic abnormalities, vascular pathology and mild immu-
nodeficiency. In addition, we have demonstrated both
clinical and laboratory improvement following treatment
with anti-TNF agents.
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